A class action lawsuit against CVS Pharmacy has reached a major milestone with the final approval of a $3.8 million settlement. The lawsuit, spearheaded by GR Firm and Bursor & Fisher P.A., challenged CVS’ marketing of its lidocaine products. Plaintiffs accused CVS of falsely advertising these products as “maximum strength,” leading to misleading claims that resulted in this legal battle.
The Claims and Allegations
Consumers filed the class action lawsuit claiming that CVS misrepresented its lidocaine patches, creams, roll-ons, and sprays as offering the “maximum strength” of lidocaine available. Plaintiffs argued that this marketing was misleading, as the products did not deliver the strongest possible concentration of lidocaine, as advertised.
In addition to the “maximum strength” claim, the lawsuit also targeted CVS’ advertisements that claimed its lidocaine patches could remain adhered to the skin for 8 to 12 hours. According to the lawsuit, these representations were untrue, further deceiving consumers.
Settlement Details
Under the terms of the settlement, CVS has agreed to pay $3.8 million to consumers who purchased the affected products. Consumers who purchased any of the eligible CVS-branded lidocaine patches, creams, roll-ons, or sprays can file a claim, and no proof of purchase is required. This opens the door for many to receive compensation without the burden of providing receipts or additional documentation.
More at the link: https://topclassactions.com/lawsuit-settlements/closed-settlements/cvs-lidocaine-false-advertising-3-8m-class-action-settlement/
